https://orcid.org/0000-0001-7978-1652
References
- Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 Jul 24;398(10297):314–324. doi: 10.1016/S0140-6736(21)00933-8
- Munshi NC, Anderson LD Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 Feb 25;384(8):705–716. doi: 10.1056/NEJMoa2024850
- Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022 Aug 11;387(6):495–505. doi: 10.1056/NEJMoa2203478
- Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023 Sep;29(9):2259–2267.
- Davis JA, Shockley A, Hashmi H. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. J Oncol Pharm Pract. 2022 Jun;28(4):960–968. doi: 10.1177/10781552211073517
- Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023 Sep 7;142(10):865–877. doi: 10.1097/HS9.0000000000000889
- Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023 May 18;141(20):2460–2469. doi: 10.1182/blood.2022017415
- Logue JM, Peres LC, Hashmi H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec 27;6(24):6109–6119. doi: 10.1182/bloodadvances.2022008320
- Dima D, Sannareddy A, Ahmed N, et al. Toxicity and efficacy outcomes of teclistamab in patients with relapsed-refractory multiple myeloma (RRMM) above the age of 70 years: a multicenter study. Blood. 2023;142(Supplement 1):3330–3330. doi: 10.1182/blood-2023-180458
- Dima D, Davis JA, Ahmed N, et al. Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience. Transplant Cell Ther. 2024 Mar;30(3):e308 1–e308 13.
- McGann M, Velayati A, Roubal K, et al. Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies. Leuk Lymphoma. 2023 Sep;64(9):1592–1595.
- Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023 Aug 1;13(1):116. doi: 10.1038/s41408-023-00879-7
- Davis JA, Dima D, Ahmed N, et al. Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed/refractory multiple myeloma. Transplant Cell Ther. 2024 Mar;30(3):298–305.
- Rejeski K, Hansen DK, Bansal R, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023 Jul 31;16(1):88. doi: 10.1186/s13045-023-01465-x
- Gagelmann N, Dima D, Merz M, et al. Development and validation of a prediction model of outcome after B-Cell maturation antigen-directed chimeric antigen receptor T-Cell therapy in relapsed/refractory multiple myeloma. J Clin Oncol. 2024 Feb 15:JCO2302232. doi: 10.1200/JCO.23.02232
- Nooka AK, Rodriguez C, Mateos MV, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2023 Nov 14;130(6):886–900. doi: 10.1002/cncr.35107
- Wesson W, Ahmed N, Rashid A, et al. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias. Eur J Haematol. 2024 Apr;112(4):538–546.
- Kampouri E, Walti CS, Gauthier J, et al. Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol. 2022 Apr;15(4):305–320.
- Lancman G, Parsa K, Kotlarz K, et al. Ivig use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov. 2023 Nov 1;4(6):440–451. doi: 10.1158/2643-3230.BCD-23-0049
- Davis JA, Sborov DW, Wesson W, et al. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transplant Cell Ther. 2023 Sep;29(9):567–571.